Status:
COMPLETED
Inflammatory Markers and Level of Cortical Hyperactivity
Lead Sponsor:
University of Chile
Conditions:
Cognition Disorder
Eligibility:
All Genders
60-80 years
Brief Summary
Alzheimer's disease (AD) is a progressive and fatal neurodegenerative disease that is manifested by severe cognitive impairment mainly from late life (\>65 years). Clinical studies have shown that bot...
Detailed Description
Alzheimer's disease (AD) is a progressive and fatal neurodegenerative disease that is manifested by severe cognitive impairment mainly from late life (\>65 years). It is now known that markers of dama...
Eligibility Criteria
Inclusion
- Adults over 60 years of age undergoing elective surgery
- Able to understand and sign an informed consent form
Exclusion
- Diagnosis of other neurological pathologies
- No active acute or chronic decompensated diseases
- No severe psychiatric illnesses
- Propofol allergy
Key Trial Info
Start Date :
August 1 2023
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
September 30 2025
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT05991830
Start Date
August 1 2023
End Date
September 30 2025
Last Update
November 20 2025
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Centro de Investigación Cínica Avanzada (CICA), Hospital Clinico de la Universidad de Chile
Santiago, RM, Chile, 7690306
2
Hospital Clinico de la Universidad de Chile
Santiago, RM, Chile, 7690306